Detailed Information on Publication Record
2020
Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer
KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL et. al.Basic information
Original name
Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer
Authors
KOLAROVA, Iveta (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Ales RYSKA (203 Czech Republic), Karel ODRAZKA, Martin DOLEZEL (203 Czech Republic), Jaroslav VANASEK (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Jiri PETERA (203 Czech Republic), Tomas BUCHLER (203 Czech Republic), Milan VOSMIK (203 Czech Republic), Katarina PETRAKOVA (203 Czech Republic), Petra TERAROVA (203 Czech Republic), Zdena VILASOVA (203 Czech Republic) and Jiří JARKOVSKÝ (203 Czech Republic, guarantor, belonging to the institution)
Edition
In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2020, 0258-851X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.155
RIV identification code
RIV/00216224:14110/20:00117213
Organization unit
Faculty of Medicine
UT WoS
000587929100043
Keywords in English
Breast cancer; triple positive; HER2-positive; hormone receptors; overall survival; trastuzumab
Tags
International impact, Reviewed
Změněno: 2/12/2020 13:08, Mgr. Tereza Miškechová
Abstract
V originále
Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.